Key clinical point: The risk for overall infection was not higher in children and adolescents with moderate-to-severe or severe atopic dermatitis (AD) treated with dupilumab vs. placebo; however, the risk for skin infections was significantly lower with dupilumab.
Major finding: Dupilumab did not increase the risk for overall infections (risk ratio [RR] 0.76; P = .051) and was associated with a reduced risk for total skin infections (RR 0.45; P = .003) compared with placebo.
Study details: This was a pooled analysis of 2 phase 3 trials including 612 adolescents or children with moderate-to-severe/severe AD who received dupilumab either as monotherapy ( LIBERTY AD ADOL ) or with concomitant topical corticosteroids ( LIBERTY AD PEDS ).
Disclosures: This study was funded by Sanofi and Regeneron Pharmaceuticals. The authors declared serving as investigators, speakers, consultants, and scientific advisors or clinical study investigators, and advisory board members or receiving honoraria and grants from several sources. Six authors declared being employees or shareholders of Sanofi and Regeneron Pharmaceuticals.
Source: Paller AS et al. Pediatr Dermatol. 2022 (Jan 26). Doi: 10.1111/pde.14909